Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 59.3 HKD -4.59%
Market Cap: 22.1B HKD

Ascentage Pharma Group International
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ascentage Pharma Group International
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Ascentage Pharma Group International
HKEX:6855
Pre-Tax Income
-ÂĄ1.1B
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Pre-Tax Income
-ÂĄ4.2B
CAGR 3-Years
24%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Pre-Tax Income
ÂĄ1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Pre-Tax Income
-ÂĄ501.1m
CAGR 3-Years
26%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Pre-Tax Income
ÂĄ67.5m
CAGR 3-Years
-69%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Pre-Tax Income
-ÂĄ142.5m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ascentage Pharma Group International
Glance View

Market Cap
20.7B HKD
Industry
Biotechnology

Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.

Intrinsic Value
74.47 HKD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Ascentage Pharma Group International's Pre-Tax Income?
Pre-Tax Income
-1.1B CNY

Based on the financial report for Jun 30, 2025, Ascentage Pharma Group International's Pre-Tax Income amounts to -1.1B CNY.

What is Ascentage Pharma Group International's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
0%

Over the last year, the Pre-Tax Income growth was -209%. The average annual Pre-Tax Income growth rates for Ascentage Pharma Group International have been -10% over the past three years .

Back to Top